Australia's most trusted
source of pharma news
Thursday, 22 January 2026
Posted 22 January 2026 AM
Merck has failed in its bid to block a trademark application by Pfizer, after arguing it should be rejected due to visual similarities with one of its own trade marks.
The German drugmaker had challenged the trademark for Pfizer's RSV vaccine injection Abrysvo, arguing it was visually similar to the trademark for Merck's MS pill Mavenclad. Both trade marks have a bi-colour circular feature to the left of the name of the drug.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.